Modulation of autoimmune responses by intravenous immunoglobulin (IVIg)

被引:28
作者
Kaveri, S
Prasad, N
Vassilev, T
Hurez, V
Pashov, A
LacroixDesmazes, S
Kazatchkine, M
机构
来源
MULTIPLE SCLEROSIS | 1997年 / 3卷 / 02期
关键词
autoimmunity; intravenous immunoglobulins; immunoregulation; immunomodulation; immunotherapy;
D O I
10.1177/135245859700300211
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Significant progresss has been made in understanding the mechanisms by which intravenous immunoglobulins (IVIg) exert immunomodulatory effects in the treatment of autoimmune diseases. A unique property of immunoglobulins is the diversity of variable (V) regions. The evidence discussed in this communication supports our notion that the diversity of V regions in IVIg preparations is a determining factor for the anti-inflammatory substitutive and immunomodulatory functions of IVIg therapy We have demonstrated the presence in IVIg, of anti-idiotypic antibodies directed against various autoantibodies. The ability of IVIg to interact through V regions with complementary V regions of antibodies and antigen receptors as well as with relevant soluble and surface molecules provides the basis for inducing the selection of immune repertoires. The study of the mechanisms by which IVIg mediates selection of autoreactive repertoires is essential for our understanding of the mechanisms underlying the emergence of pathological autoimmunity and of the physiological role of natural antibodies in the establishment and maintenance of tolerance to self and homeostasis of autoreactivity in healthy individuals.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 60 条
  • [1] ANTI-CYTOKINE NATURE OF NATURAL HUMAN-IMMUNOGLOBULIN - ONE POSSIBLE MECHANISM OF THE CLINICAL EFFECT OF INTRAVENOUS IMMUNOGLOBULIN THERAPY
    ABE, Y
    HORIUCHI, A
    MIYAKE, M
    KIMURA, S
    [J]. IMMUNOLOGICAL REVIEWS, 1994, 139 : 5 - 19
  • [2] ADIB M, 1990, J IMMUNOL, V145, P3807
  • [3] AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
  • [4] BASTA M, 1989, BLOOD, V74, P326
  • [5] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN EXERTS ITS BENEFICIAL EFFECT IN PATIENTS WITH DERMATOMYOSITIS BY BLOCKING ENDOMYSIAL DEPOSITION OF ACTIVATED COMPLEMENT FRAGMENTS
    BASTA, M
    DALAKAS, MC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05) : 1729 - 1735
  • [6] MECHANISM OF THERAPEUTIC EFFECT OF HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN - ATTENUATION OF ACUTE, COMPLEMENT-DEPENDENT IMMUNE DAMAGE IN A GUINEA-PIG MODEL
    BASTA, M
    KIRSHBOM, P
    FRANK, MM
    FRIES, LF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) : 1974 - 1981
  • [7] AUTOANTIBODIES TO CYTOKINES - FRIENDS OR FOES
    BENDTZEN, K
    SVENSON, M
    JONSSON, V
    HIPPE, E
    [J]. IMMUNOLOGY TODAY, 1990, 11 (05): : 167 - 169
  • [8] BERCHTOLD P, 1989, BLOOD, V74, P2414
  • [9] RANDOMIZED TRIAL OF INTRAVENOUS IMMUNOGLOBULIN-G, INTRAVENOUS ANTI-D, AND ORAL PREDNISONE IN CHILDHOOD ACUTE IMMUNE THROMBOCYTOPENIC PURPURA
    BLANCHETTE, V
    IMBACH, P
    ANDREW, M
    ADAMS, M
    MCMILLAN, J
    WANG, E
    MILNER, R
    ALI, K
    BARNARD, D
    BERNSTEIN, M
    CHAN, KW
    ESSELTINE, D
    DEVEBER, B
    ISRAELS, S
    KOBRINSKY, N
    LUKE, B
    [J]. LANCET, 1994, 344 (8924) : 703 - 707
  • [10] SOLUBLE CD4, CD8, AND HLA MOLECULES IN COMMERCIAL IMMUNOGLOBULIN PREPARATIONS
    BLASCZYK, R
    WESTHOFF, U
    GROSSEWILDE, H
    [J]. LANCET, 1993, 341 (8848) : 789 - 790